Radiation therapy combined with immunotherapy for advanced lung cancer

This trial is testing whether adding a highly focused radiation treatment called liver stereotactic ablative radiotherapy (L-SABR) to standard immunotherapy improves outcomes for people with advanced lung cancer that has spread to the liver. Half of participants will receive the standard immunotherapy drugs alone, while the other half will receive the same immunotherapy plus the specialized radiation therapy. The goal is to see if combining these two approaches works better than immunotherapy by itself.

Immunotherapy drugs have helped many people with advanced lung cancer, but not everyone responds well to them. Researchers believe that adding targeted radiation therapy to the liver may help boost the body's immune response and improve how well the immunotherapy works.